CorMedix Inc. (CRMD): Price and Financial Metrics

CorMedix Inc. (CRMD)

Today's Latest Price: $5.28 USD

0.13 (-2.40%)

Updated Sep 23 4:00pm

Add CRMD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

CRMD Stock Summary

  • CRMD's price/sales ratio is 966.8; that's higher than the P/S ratio of 99.39% of US stocks.
  • With a year-over-year growth in debt of -99.97%, CorMedix Inc's debt growth rate surpasses just 1.15% of about US stocks.
  • As for revenue growth, note that CRMD's revenue has grown -70.77% over the past 12 months; that beats the revenue growth of only 2.14% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CorMedix Inc are LPCN, INO, RGLS, MRSN, and ADAP.
  • CRMD's SEC filings can be seen here. And to visit CorMedix Inc's official web site, go to
CRMD Daily Price Range
CRMD 52-Week Price Range

CRMD Stock Price Chart Technical Analysis Charts

CRMD Price/Volume Stats

Current price $5.28 52-week high $8.14
Prev. close $5.41 52-week low $2.16
Day low $4.93 Volume 749,387
Day high $5.42 Avg. volume 345,566
50-day MA $4.79 Dividend yield N/A
200-day MA $5.23 Market Cap 164.94M

CorMedix Inc. (CRMD) Company Bio

CorMedix Inc., a commercial pharmaceutical and medical device company, intends to in-license, develop, and commercialize prophylactic and therapeutic for the prevention and treatment of infectious and inflammatory diseases. The company was founded in 2006 and is based in Bridgewater, New Jersey.

CRMD Latest News Stream

Event/Time News Detail
Loading, please wait...

CRMD Latest Social Stream

Loading social stream, please wait...

View Full CRMD Social Stream

Latest CRMD News From Around the Web

Below are the latest news stories about CorMedix Inc that investors may wish to consider to help them evaluate CRMD as an investment opportunity.

NGM Bio Aldafermin Data, And Other News: The Good, Bad And Ugly Of Biopharma

NGM Bio reports positive Phase 2 data for Aldafermin NGM Biopharmaceuticals Inc. (NGM) reported final data from its 24-week Phase 2 study of aldafermin 1 mg. The trial involved patients with non-alcoholic steatohepatitis. The readout included a new analysis of data gathered from Cohort 4 consisting of NASH patients with...

Avisol Capital Partners on Seeking Alpha | September 6, 2020

Insider Buys CorMedix's Stock

Kaplan Myron filed a Form 4 with the SEC on Tuesday, February 25. The insider bought 15,300 shares of CorMedix Inc. (AMEX:CRMD) at an average price of $4.27. After the transaction, the executive's stake in CorMedix moved to 150,034 shares. CorMedix was trading 3% lower from the previous closing price.The Importance of Insider Transactions Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision.When an insider buys stock after an important sell off, that can indicate the insider's faith in the success of the organization. Henceforth, if the stock is bought at new highs, it might be because the insider feels that the stock is not overvalued. Insiders who sell stock at ne...

Yahoo | September 4, 2020

CorMedix +7% on FDA acceptance for filing and priority review of Defencath

FDA has accepted CorMedix (CRMD) +7% filing of new drug application for Defencath its product candidate to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections.The FDA had previously granted a rolling submission and review, which the Company completed at...

Seeking Alpha | August 31, 2020

CorMedix Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Defencath

* FDA sets PDUFA goal date of February 28, 2021 * Potentially the first antibacterial and antifungal catheter lock solution in the US to prevent catheter related infections in hemodialysis patients BERKELEY HEIGHTS, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s submitted New Drug Application (NDA) for Defencath™, its product candidate to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (CRBSI). The FDA had previously gr...

Yahoo | August 31, 2020

CorMedix (CRMD) Jumps: Stock Rises 9.8%

CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Yahoo | August 19, 2020

Read More 'CRMD' Stories Here

CRMD Price Returns

1-mo 11.16%
3-mo -13.44%
6-mo 46.67%
1-year -30.43%
3-year 124.68%
5-year -56.36%
YTD -27.47%
2019 12.87%
2018 158.00%
2017 -67.32%
2016 -24.63%
2015 6.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7781 seconds.